SEC Form 4 · accession 0001853529-26-000001
Edgewise Therapeutics, Inc. · EWTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan J Russell
Officer — Chief Scientific Officer · Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 5:21 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001710072
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 1, 2026 | M | 130,352 | $0.45 | A | 154,907 | D | |
| Common Stock | Jul 1, 2026 | M | 69,648 | $0.18 | A | 224,555 | D | |
| Common StockF2 | Jul 1, 2026 | S | 130,352 | $39.406 | D | 94,203 | D | |
| Common StockF3 | Jul 1, 2026 | S | 69,648 | $39.4089 | D | 24,555 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $0.45 | Jul 1, 2026 | M | 130,352 | D | — | Aug 30, 2028 | Common Stock | 130,352 | 0 | D |
| Stock Option (Right to Buy)F5 | $0.18 | Jul 1, 2026 | M | 69,648 | D | — | Jun 27, 2032 | Common Stock | 69,648 | 1,077,717 | D |
Explanation of responses
- F1Includes 107 shares purchased on November 15, 2025 and 1,048 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.905, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F41/48th of the shares subject to the option vest each month beginning on September 10, 2018, subject to the Reporting Person continuing as a service provider through each vest date.
- F51/48th of the shares subject to the option vest each month beginning on July 27, 2017, subject to the Reporting Person continuing as a service provider through each vest date.